In rodentdrug discrimination tests, (S)-βk-5-MAPB fully substitutes for MDMA whereas (R)-βk-5-MAPB partially substitutes for MDMA anddextroamphetamine at different doses, (R)-βk-5-MAPB and (S)-βk-5-MAPB both generalize to dextroamphetamine, and (S)-βk-5-MAPB but not (R)-βk-5-MAPB substitutes forDOM.[4] Hence, (S)-βk-5-MAPB showsentactogen-,psychedelic-, andstimulant-like effects, whereas (R)-βk-5-MAPB shows more stimulant-like effects, some entactogen-like effects, and no psychedelic-like effects.[4] In other tests, both (S)-βk-5-MAPB and (R)-βk-5-MAPB showed stimulant-likepro-impulsive effects, but (S)-βk-5-MAPB was more potent than (R)-βk-5-MAPB.[8]
^abWO 2021/252538, Baggott M, "Advantageous benzofuran compositions for mental disorders or enhancement", published 16 December 2021, assigned to Tactogen Inc.
^abWO 2023/107653, Baggott MJ, Lofthus SJ, De Leona XM, Singh A, Hudgins CJ, "Benzofuran salt morphic forms and mixtures for the treatment of mental disorders or mental enhancement", published 21 September 2023, assigned to Tactogen Inc.
^abcJohnson C, Burroughs R, Walther D, Baggott M, Baumann M, Baker L (June 2023).Behavioral Assessments and Neurochemical Assays Differentiate the Effects of 1-(1-Benzofuran-5-yl)-2-(methylamino) propan-1-one Hydrochloride (BK-5-MAPB) Enantiomers(PDF).June 17-21, 2023: 85th CPDD Scientific Meeting, Denver, CO.Results: S-BK-5-MAPB produced dose-dependent increases in MDMA-lever responses and full substitution at 0.64 and 1.27 mg/kg; R-BK-5-MAPB produced less than 30% MDMA-lever responding. Both enantiomers increased distance traveled in a dose-dependent manner that was statistically significant compared to saline-treated controls (P= 0.0001). Both enantiomers were substrate-type releasers at all three transporters. The S-enantiomer displayed an MDMA-like profile with greater potency at SERT than DAT (DAT/SERT ratio of 0.6), while R-BK-5-MAPB had a typical stimulant profile (DAT/SERT ratio of 18). Both enantiomers had higher potency at DAT than NET (DAT/NET ratios of 2.7 and 1.9 for the S- and R-enantiomer, respectively). [...] Because they have reduced potency at NET, these novel substances may have utility in elucidating the contributions of NET to MDMA-like and typical stimulant effects.
^WO 2023/107715, Baggott M, Dalziel S, "Specialized combinations for mental disorders or mental enhancement", published 15 June 2023, assigned to Tactogen Inc.
^Johnson C, Burroughs R, Walther D, Baggott M, Baumann M, Baker L (2024). "Behavioral Assessments and Neurochemical Assays Differentiate the Effects of 1-(1-Benzofuran-5-yl)-2-(methylamino) propan-1-one Hydrochloride (BK-5-MAPB) Enantiomers".Drug and Alcohol Dependence.260 110018.doi:10.1016/j.drugalcdep.2023.110018.
^US 20230150963, Matthew Baggott, "Advantageous benzofuran compositions for mental disorders or enhancement", published 2023 May 18, assigned toTactogen
